Precision Oncology Today
Modeling Disease in 3D
How do researchers, looking to create more realistic disease models—along with more targeted therapies—overcome the shortcomings of these models? Increasingly, it is via the use of human organoids. Advances over the past dozen or so years in the methods for growing these three-dimensional models has resulted in a significant uptick in their use in precision medicine research.
Using the Epigenome to Guide Development of Gene Edited Therapies
IPM's Helen Albert spoke with Poulami Chaudhuri, PhD, the CEO and co-founder of Helex, about founding an international start-up during a pandemic, being a female biotech founder in India, the importance of looking at DNA in 3D when designing therapies, and the future of the company.
Trending on Inside Precision Medicine
Reclassifying a New Era in Laboratory Testing Regulation
With IVDR coming into force in the EU, there has been a lack of clarity as to what it means and whom it will impact. IPM spoke with Amélie Martinez, who has been leading Saphetor’s preparations for IVDR, to get some guidance on what the new regulation means for labs in Europe.
Revolutionizing Biopharma Manufacturing with Fully Automated Droplet Digital™ PCR
From development to quality control and ongoing therapeutic evaluation, absolute quantification of nucleic acids can be the key to taking your biopharma product to the next level.
How CAR T Therapy Reimagines Cancer Treatment and More
Chimeric antigen receptor T cell therapy, commonly referred to as CAR T therapy, is an intervention that uses a patient’s own cells to fight...